We focus our efforts on 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT), a naturally-occurring psychoactive substance from the tryptamine class.
5-MeO-DMT is a serotonergic psychedelic, a class of psychoactive drugs that act primarily through an agonist action on serotonin receptors and cause an altered state of consciousness.
In vivo and in vitro research from academic studies suggest that 5-MeO-DMT acts primarily as a serotonin agonist, active at both the 5-HT1A and 5-HT2A receptors, which are expressed in neurons in different areas of the central nervous system.
5-MeO-DMT appears to have a higher affinity for the 5-HT1A receptor subtype and a more selective pattern of distribution across various neurotransmitter receptor types compared to other tryptamines, such as psilocin and N,N-Dimethyltryptamine, or DMT, both of which have stronger affinity for the 5-HT2A receptor subtype and a less selective receptor binding profile
We have filed four patent applications covering novel aerosol compositions of matter of 5-MeO-DMT, novel manufacturing methods for the purification of 5-MeO-DMT, high purity 5-MeO-DMT and novel uses of 5-MeO-DMT in various disorders.
We are committed to exploring additional opportunities with 5-MeO- DMT through continuous research and development and will continue to seek patent protection for all our innovations.